Tocainide is considered a class I (membrane-stabilizing) antidysB rhythmic agent that demonstrates rapid rates of attachment and dissociation to sodium channels. Like lidocaine, tocainide produces a dose-dependent decrease in potassium and sodium conductance that results in decreased excitability of myocardial cells. Automaticity, conduction velocity, and effective refractory periods are decreased at therapeutic levels. Little or no increases in PR intervals, QRS complexes, or QT intervals are seen at therapeutic levels. Like lidocaine, tocainide has little, if any effect, on autonomic tone.
Tolazoline is approved and indicated for the reversal of effects associated with xylazine in horses. It has also been used for this purpose in a variety of other species as well, but less safety and efficacy data is available. In humans, the primary uses for tolazoline are: treatment of persistent pulmonary hypertension in newborns, adjunctive treatment and diagnosis of peripheral vasospastic disorders, and as a provocative test for glaucoma after subconjunctival injection.
劑量數字暫停提供：VetPro 的劑量改依 DRUGAPI 藥物資料庫對外的內容，DRUGAPI 目前不提供可直接計算的劑量。下方列出 DRUGAPI 的審查結論與劑量審查引用的來源；計算機可手動輸入劑量換算。
缺少可強制的精確產品／鹽基／強度、心室性心律不整與 Holter、心功能／傳導、角膜、腎臟、血液、法域及追蹤閘門。
依出現頻率分組；嚴重副作用獨立列出，臨床上需立即辨識。